Risk of Serious Infections in Patients Treated With Biologic or Targeted‐synthetic Disease Modifying Antirheumatic Drugs in Qatar
Patients with inflammatory conditions managed with b/tsDMARDs are at significant risk of SIs, which necessitate appropriate patient selection weighing benefits and risks, as well as careful long-term management that include patient education and relevant preventive therapy.
Authors
- Nabeel Abdulla (ORCID: https://orcid.org/0000-0001-7787-8717)
- Sreethish Sasi (ORCID: https://orcid.org/0000-0002-4098-0459)
- Reem Elajez (ORCID: https://orcid.org/0000-0001-7824-3203)
- Abdullatif Al‐Khal (ORCID: https://orcid.org/0000-0003-3737-8253)
- Javed Iqbal (ORCID: https://orcid.org/0000-0003-2627-685X)
- Sief Khasawneh (ORCID: https://orcid.org/0000-0001-9144-9118)
- Hamad Abdel Hadi (ORCID: https://orcid.org/0000-0001-8647-1695)
- Ali S. Omrani (ORCID: https://orcid.org/0000-0001-5309-6358)
- Maisa Ali (ORCID: https://orcid.org/0000-0003-4023-2909)
- Masautso Chaponda (ORCID: https://orcid.org/0000-0002-5141-6861)
- Muna Al Maslamani
- Mohamed Ataelmanan
- Hind Saqallah
Institutions
- Hamad Medical Corporation (QA)
- Qatar University (QA)
Publication Details
- Journal
- Immunity Inflammation and Disease
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1002/iid3.70195
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Qatar National Library